Finance Watch: Three Newly Public Companies Face Mixed Reception In Early Trading

Pyxis, Theseus And Cognition IPOs Raise $373.2m

Also, two more health care-focused SPACs went public, Centessa obtained up to $300m in debt, three new venture capital funds launched and Intergalactic debuted with a $75m series A round.

Pyxis Oncology, Theseus Pharmaceuticals, Inc. and Cognition Therapeutics, Inc. launched initial public offerings in the US between 6 and 8 October, raising $373.2m combined, but the first three companies to go public in the US this month had mixed stock price performance after their IPOs.

The post-offering fluctuations were not surprising given the share price performance of other biopharma firms that have gone public this...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Abivax Over The Moon As Obefazimod Storms Phase III

23 Jul 2025

• By Kevin Grogan

Stock shoots up over 460% on positive results in two ulcerative colitis trials of the oral first-in-class candidate.

Scrip M&A Podcast: Is Biopharma M&A In A Holding Pattern Or A ‘New Normal’

23 Jul 2025

• By Joseph Haas

Scrip discusses the latest M&A activity and trends with CEO Shawn Titcomb of Allele Capital and Cheryl Reicin, a partner focused on international life sciences activity at Mintz.

Finance Watch: Sarepta’s Debt Woes Grow With Elevidys Shipment Pause

22 Jul 2025

• By Mandy Jackson

Public Company Edition: Sarepta restructured after stopping shipments of its Elevidys for some patients to ease future debt pressures, but now it has stopped shipments to all patients. Also, Madrigal secured up to $500m in new debt, Cogent closed a $230m offering and other financings.

Avalyn Raises $100m Series D To Advance Inhaled Pulmonary Fibrosis Candidates

22 Jul 2025

• By Joseph Haas

Looking to improve on the efficacy and safety of Roche’s Esbriet and BI’s Ofev, Avalyn has inhalable formulations of those drugs in Phase IIb and Phase I, respectively.